Literature DB >> 12773511

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions.

Jason D Marshall1, Karen Fearon, Christi Abbate, Sandhya Subramanian, Priscilla Yee, Josh Gregorio, Robert L Coffman, Gary Van Nest.   

Abstract

Recent reports have identified two major classes of CpG motif-containing oligodeoxynucleotide immunostimulatory sequences (ISS): uniformly modified phosphorothioate (PS) oligodeoxyribonucleotides (ODNs), which initiate B cell functions but poorly activate dendritic cells (DCs) to make interferon (IFN)-alpha, and chimeric PS/phosphodiester (PO) ODNs containing runs of six contiguous guanosines, which induce very high levels of plasmacytoid DC (PDC)-derived IFN-alpha but poorly stimulate B cells. We have generated the first reported ISS, C274, which exhibits very potent effects on all human immune cells known to recognize ISS. C274 is a potent inducer of IFN-gamma/IFN-alpha from peripheral blood mononuclear cells and exhibits accelerated kinetics of activity compared with standard ISS. This ODN also effectively stimulates B cells to proliferate, secrete cytokines, and express costimulatory antigens. In addition, C274 specifically activates PDCs to undergo maturation and secrete cytokines, including very high levels of IFN-alpha. Sequence variation studies based on C274 were used to identify the general motif requirements for this novel and distinct class of ISS. In contrast, chimeric PO/PS CpG-containing ODNs with polyguanosine sequences exert a differential pattern of ISS activity compared with C274, perhaps in part as a result of their greatly different structural nature. This pattern is composed of high IFN-alpha/IFN-gamma induction and low DC maturation in the absence of B cell stimulation. In conclusion, we have generated a novel class of ISS that transcends the limitations ascribed to classes described previously in that it provides excellent stimulation of B cells and simultaneously activates PDCs to differentiate and secrete large amounts of type I IFN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773511     DOI: 10.1189/jlb.1202630

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  70 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Of men, mice and pigs: looking at their plasmacytoid dendritic cells [corrected].

Authors:  Hubertus Hochrein; Hermann Wagner
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

3.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

4.  Impact of site-specific nucleobase deletions on the arthritogenicity of DNA.

Authors:  Jan L Bjersing; Andrej Tarkowski; Ekambar R Kandimalla; Helen Karlsson; Sudhir Agrawal; L Vincent Collins
Journal:  Inflammation       Date:  2004-06       Impact factor: 4.092

5.  Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Yukui Li; Dong Yu; Daqing Wang; Yan-Ping Cong; Sam S Song; Jimmy X Tang; Tim Sullivan; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-28       Impact factor: 11.205

6.  Characterization of plasmacytoid dendritic cells in bone marrow of pig-tailed macaques.

Authors:  R Keith Reeves; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

7.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

8.  CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis.

Authors:  Hong-Tao Li; Zhuang-Gui Chen; Yu-Sen Lin; Hui Liu; Jin Ye; Xiao-Ling Zou; Yan-Hong Wang; Hai-Ling Yang; Tian-Tuo Zhang
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 9.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

10.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.